We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark
Read MoreHide Full Article
For Immediate Release
Chicago, IL –November 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway BRK.B), AbbVie (ABBV - Free Report) , Booking Holdings (BKNG - Free Report) , HCA Healthcare (HCA - Free Report) and Kimberly-Clark (KMB - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, AbbVie & Booking Holdings
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway, AbbVie and Booking Holdings. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Strong Buy-rankedBerkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+17.5% vs. +12.7%). Berkshire Hathaway’s third-quarter earnings nearly doubled year over year on solid results across all segments.
The Zacks analyst thinks Berkshire Hathaway’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on buyouts. Demand for utilities is expected to rise in the future and drive earnings growth.
Continued insurance business growth also fuels increase in float. A sturdy capital level provides further impetus. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern.
Huge capital expenses due to railroad operations pose concerns. Capital expenditure is estimated to be $9.8 billion in 2018.
Shares of AbbVie have lost -7.3% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +8%. AbbVie beat estimates for earnings while slightly missing the same for sales in the third quarter.
The Zacks analyst likes AbbVie’s key drug, Humira which has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential. Mavyret’s launch has also been stronger than expected. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta.
Moreover, AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. Direct biosimilar competition to Humira in Europe from October may erode revenues.
Booking Holdings’ shares have gained +9.7% year to date, outperforming the Zacks Internet Commerce industry, which has remained flat over the same period. Booking Holdings reported third quarter results wherein both earnings and revenues have grown year over year. Solid growth in the booked room nights and strong momentum in global accommodation space contributed well to the gross bookings growth.
Further, robust agency model continued to aid the company’s position in the international markets. Also, strong efforts toward ramping up of merchant business were positive. The Zacks analyst thinks secular growth trend in the online travel booking market, growing mobile usage penetration and improving ADRs are tailwinds.
Moreover, the company’s strong position in international markets, growth opportunities in the domestic market and good execution of marketing strategies are major positives. However, sluggishness in the rental car days poses risk. Also, rising advertising spend and occupancy tax litigation are concerns.
Other noteworthy reports we are featuring today include HCA Healthcare and Kimberly-Clark.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark
For Immediate Release
Chicago, IL –November 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway BRK.B), AbbVie (ABBV - Free Report) , Booking Holdings (BKNG - Free Report) , HCA Healthcare (HCA - Free Report) and Kimberly-Clark (KMB - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, AbbVie & Booking Holdings
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway, AbbVie and Booking Holdings. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Strong Buy-rankedBerkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+17.5% vs. +12.7%). Berkshire Hathaway’s third-quarter earnings nearly doubled year over year on solid results across all segments.
The Zacks analyst thinks Berkshire Hathaway’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on buyouts. Demand for utilities is expected to rise in the future and drive earnings growth.
Continued insurance business growth also fuels increase in float. A sturdy capital level provides further impetus. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern.
Huge capital expenses due to railroad operations pose concerns. Capital expenditure is estimated to be $9.8 billion in 2018.
Shares of AbbVie have lost -7.3% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +8%. AbbVie beat estimates for earnings while slightly missing the same for sales in the third quarter.
The Zacks analyst likes AbbVie’s key drug, Humira which has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential. Mavyret’s launch has also been stronger than expected. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta.
Moreover, AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. Direct biosimilar competition to Humira in Europe from October may erode revenues.
Booking Holdings’ shares have gained +9.7% year to date, outperforming the Zacks Internet Commerce industry, which has remained flat over the same period. Booking Holdings reported third quarter results wherein both earnings and revenues have grown year over year. Solid growth in the booked room nights and strong momentum in global accommodation space contributed well to the gross bookings growth.
Further, robust agency model continued to aid the company’s position in the international markets. Also, strong efforts toward ramping up of merchant business were positive. The Zacks analyst thinks secular growth trend in the online travel booking market, growing mobile usage penetration and improving ADRs are tailwinds.
Moreover, the company’s strong position in international markets, growth opportunities in the domestic market and good execution of marketing strategies are major positives. However, sluggishness in the rental car days poses risk. Also, rising advertising spend and occupancy tax litigation are concerns.
Other noteworthy reports we are featuring today include HCA Healthcare and Kimberly-Clark.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.